{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:27:15Z","timestamp":1791412035483,"version":"4.3.3"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Over the past 15 years, more than 1500 patients have received HSCT, mostly autologous, as treatment for a severe autoimmune disease (AD). More than 1000 of these have been registered in the European Group for Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) combined database. A recent retrospective analysis of 900 patients showed that the majority had multiple sclerosis (MS; n = 345) followed by systemic sclerosis (SSc; n = 175), systemic lupus erythematosus (SLE; n = 85), rheumatoid arthritis (RA; n = 89), juvenile idiopathic arthritis (JIA; n = 65), and idiopathic cytopenic purpura (ITP; n = 37). An overall 85% 5-year survival and 43% progression-free survival was seen, with 100-day transplantation-related mortality (TRM) ranging between 1% (RA) and 11% (SLE and JIA). Approximately 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many patients, such as in those with SSc, morphological improvement such as reduction of skin collagen and normalization of microvasculature was documented beyond any predicted known effects of intense immunosuppression alone. The high TRM was in part related to conditioning intensity, comorbidity, and age, but until the results of the 3 prospective randomized trials are known, an evidence-based modification of the conditioning regimen will not be possible.1 In recent years, multipotent mesenchymal stromal cells (MSCs) have been tested in various AD, exploiting their immune-modulating properties and apparent low acute toxicity. Despite encouraging small phase 1\/2 studies, no positive data from randomized, prospective studies are as yet available in the peer-reviewed literature.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.280","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"280-284","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":70,"title":["Successes and Failures of Stem Cell Transplantation in Autoimmune Diseases"],"prefix":"10.1182","volume":"2011","author":[{"given":"Alan","family":"Tyndall","sequence":"first","affiliation":[{"name":"University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111716260866100_B1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica"},{"key":"2019111716260866100_B2","first-page":"237","article-title":"Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia","volume":"1","author":"Jacobs","year":"1986","journal-title":"Bone Marrow Transplant"},{"key":"2019111716260866100_B3","first-page":"333","article-title":"Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation","volume":"8","author":"Knaan-Shanzer","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"2019111716260866100_B4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/ard.55.10.779","article-title":"Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease","volume":"55","author":"Tamm","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"2019111716260866100_B5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.bmt.1700727","article-title":"Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT)","volume":"19","author":"Tyndall","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2019111716260866100_B6","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.bmt.1704892","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases","volume":"35","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2019111716260866100_B7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","article-title":"Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system","volume":"113","author":"Alexander","year":"2009","journal-title":"Blood"},{"key":"2019111716260866100_B8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20041679","article-title":"Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients","volume":"201","author":"Muraro","year":"2005","journal-title":"J Exp Med"},{"key":"2019111716260866100_B9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/08916930802200182","article-title":"Regulatory T cells in autologous stem cell transplantation for autoimmune disease","volume":"41","author":"van Wijk","year":"2008","journal-title":"Autoimmunity"},{"key":"2019111716260866100_B10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/kel451","article-title":"Skin involvement in scleroderma\u2013where histological and clinical scores meet","volume":"46","author":"Verrecchia","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2019111716260866100_B11","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1371\/journal.pone.0001452","article-title":"Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?","volume":"3","author":"Fleming","year":"2008","journal-title":"PLoS One"},{"key":"2019111716260866100_B12","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/rheumatology\/ker125","article-title":"Nail fold capillaroscopy differs widely between systemic sclerosis and chronic graft vs host disease of the skin","volume":"50","author":"Aschwanden","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2019111716260866100_B13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1126\/science.327.5967.772","article-title":"Immunology. Replacing an immune system gone haywire","volume":"327","author":"Couzin-Frankel","year":"2010","journal-title":"Science"},{"key":"2019111716260866100_B14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/acr.20322","article-title":"Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin","volume":"63","author":"Bartoloni","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2019111716260866100_B15","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.22656","article-title":"Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial","volume":"56","author":"Brinkman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2019111716260866100_B16","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/ard.2010.139246","article-title":"Minimal T-cell requirements for triggering haemophagocytosis associated with Epstein-Barr virus-driven B-cell proliferation: a clinical case study","volume":"70","author":"Daikeler","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2019111716260866100_B17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.bmt.1704550","article-title":"Acquired hemophilia-A in a patient with multiple sclerosis treated with autologous hematopoietic stem cell transplantation and interferon beta-1a","volume":"34","author":"Kaloyannidis","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"2019111716260866100_B18","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1136\/ard.2004.033332","article-title":"Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration","volume":"64","author":"Verburg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2019111716260866100_B19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/bmt.2008.424","article-title":"Allogeneic hematopoietic SCT for patients with autoimmune diseases","volume":"44","author":"Daikeler","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2019111716260866100_B20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14653240500319234","article-title":"Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement","volume":"7","author":"Horwitz","year":"2005","journal-title":"Cytotherapy"},{"key":"2019111716260866100_B21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2005.02.001","article-title":"Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients","volume":"11","author":"Lazarus","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111716260866100_B22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/bmt.2009.63","article-title":"Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks","volume":"43","author":"Tyndall","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2019111716260866100_B23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nm.1905","article-title":"Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production","volume":"15","author":"N\u00e9meth","year":"2009","journal-title":"Nat Med"},{"key":"2019111716260866100_B24","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-07-0731","article-title":"Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells","volume":"13","author":"Dwyer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2019111716260866100_B25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.stem.2008.08.008","article-title":"All MSCs are pericytes?","volume":"3","author":"Caplan","year":"2008","journal-title":"Cell Stem Cell"},{"key":"2019111716260866100_B26","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI39675","article-title":"EMT: when epithelial cells decide to become mesenchymal-like cells","volume":"119","author":"Kalluri","year":"2009","journal-title":"J Clin Invest"},{"key":"2019111716260866100_B27","first-page":"50","article-title":"Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study","volume":"4","author":"Mohyeddin Bonab","year":"2007","journal-title":"Iran J Immunol"},{"key":"2019111716260866100_B28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","article-title":"Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study","volume":"227","author":"Yamout","year":"2010","journal-title":"J Neuroimmunol"},{"key":"2019111716260866100_B29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch Neurol"},{"key":"2019111716260866100_B30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1479-5876-7-29","article-title":"Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis","volume":"7","author":"Riordan","year":"2009","journal-title":"J Transl Med"},{"key":"2019111716260866100_B31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/1352458509104590","article-title":"Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis","volume":"15","author":"Liang","year":"2009","journal-title":"Mult Scler"},{"key":"2019111716260866100_B32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/DCR.0b013e3181973487","article-title":"Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial","volume":"52","author":"Garcia-Olmo","year":"2009","journal-title":"Dis Colon Rectum"},{"key":"2019111716260866100_B33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/gut.2010.214841","article-title":"Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease","volume":"60","author":"Ciccocioppo","year":"2011","journal-title":"Gut"},{"key":"2019111716260866100_B34","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/gut.2010.215152","article-title":"Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study","volume":"59","author":"Duijvestein","year":"2010","journal-title":"Gut"},{"key":"2019111716260866100_B35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/rheumatology\/ken407","article-title":"Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis","volume":"48","author":"Nevskaya","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2019111716260866100_B36","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.leu.2404996","article-title":"Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L","volume":"22","author":"Christopeit","year":"2008","journal-title":"Leukemia"},{"key":"2019111716260866100_B37","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2019111716260866100_B38","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/art.27548","article-title":"Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus","volume":"62","author":"Sun","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2019111716260866100_B39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/0961203309348983","article-title":"Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients","volume":"19","author":"Carrion","year":"2010","journal-title":"Lupus"},{"key":"2019111716260866100_B40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nrrheum.2010.80","article-title":"Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE","volume":"6","author":"Liang","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"2019111716260866100_B41","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/art.27736","article-title":"Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells","volume":"62","author":"Bocelli-Tyndall","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2019111716260866100_B42","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood-2009-05-219907","article-title":"Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation","volume":"115","author":"Tarte","year":"2010","journal-title":"Blood"},{"key":"2019111716260866100_B43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/rheumatology\/kel267","article-title":"Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro","volume":"46","author":"Bocelli-Tyndall","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2019111716260866100_B44","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1089\/ten.tea.2011.0131","article-title":"The survey on cellular and engineered tissue therapies in Europe in 2009","volume":"17","author":"Martin","year":"2011","journal-title":"Tissue Eng Part A"},{"key":"2019111716260866100_B45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1352458509359727","article-title":"The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group","volume":"16","author":"Freedman","year":"2010","journal-title":"Mult Scler"},{"key":"2019111716260866100_B46","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ncprheum0814","article-title":"Why do we need noncommercial, investigator-initiated clinical trials?","volume":"4","author":"Tyndall","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2019111716260866100_B47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.stem.2009.07.013","article-title":"The ISSCR: who are we and where are we going?","volume":"5","author":"Weissman","year":"2009","journal-title":"Cell Stem Cell"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/280\/1493635\/bep00111000280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/280\/1493635\/bep00111000280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T21:26:30Z","timestamp":1574025990000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/280\/96996\/Successes-and-Failures-of-Stem-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.280","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}